Stephens Consulting, LLC Supernus Pharmaceuticals, Inc. Transaction History
Stephens Consulting, LLC
- $399 Billion
- Q1 2025
A detailed history of Stephens Consulting, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 10 shares of SUPN stock, worth $308. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10Holding current value
$308% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
301Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$321 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$190 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$149 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$88.8 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$81.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.65B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...